To further enhance tumor specificity and maximize therapeutic efficacy, liposomal formulations have been engineered with surface ligands—such as angiopep-2 or CD133 antibodies conjugated to PEGylated liposomes in an LUV structure—that facilitate active targeting [54]. The gene discussed is PROM1; the disease is neoplasm.